Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Epigenetic alterations frequently participate in the onset of hematological malignancies. Histone deacetylases (HDACs) are essential for regulating gene transcription and various signaling pathways. Targeting HDACs has become a novel treatment option for hematological malignancies. Chidamide is the...

Full description

Saved in:
Bibliographic Details
Published in:Hematological oncology 2023-08, Vol.41 (3), p.301-309
Main Authors: Cao, Han‐Yu, Li, Ling, Xue, Sheng‐Li, Dai, Hai‐Ping
Format: Article
Language:English
Subjects:
Apoptosis
Cell cycle
Chemotherapy
chidamide
Epigenetics
FDA approval
HDAC inhibitors
HDAC2 protein
Health services
hematological malignancy
Hematology
Histone deacetylase
Histones
Leukemia
Lymphoma
Malignancy
mechanism
Multiple myeloma
Myelodysplastic syndrome
Myelodysplastic syndromes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epigenetic alterations frequently participate in the onset of hematological malignancies. Histone deacetylases (HDACs) are essential for regulating gene transcription and various signaling pathways. Targeting HDACs has become a novel treatment option for hematological malignancies. Chidamide is the first oral selective HDAC inhibitor for HDAC1, HDAC2, HDAC3, and HDAC10 and was first approved for the treatment of R/R peripheral T‐cell lymphoma by the China Food and Drug Administration in 2014. Chidamide was also approved under the name Hiyasta (HBI‐8000) in Japan in 2021. In vitro studies revealed that chidamide could inhibit proliferation and induce apoptosis via cell cycle arrest and the regulation of apoptotic proteins. In clinical studies, chidamide was also efficacious in multiple myeloma, acute leukemia and myelodysplastic syndrome. This review includes reported experimental and clinical data on chidamide monotherapy or chidamide treatment in combination with chemotherapy for various hematological malignancies, offering a rationale for the renewed exploration of this drug.
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.3088